WorldAtNet Flagship Health & Science | Blood Medicine | Genetics | Transfusion Science
Published: September 24, 2026
For more than half a century, one of the strangest puzzles in blood medicine remained unresolved.
Scientists knew that a particular marker could be found on the red blood cells of almost everybody. They knew that a very small number of people appeared to lack it. They knew that some patients could produce antibodies against it, and that those antibodies could become important when blood transfusion was required.
But they did not know exactly what the mysterious marker was made of or which gene was responsible for putting it on the surface of a red blood cell.
The mystery began in 1972 with the discovery of what became known as the AnWj antigen.
Now the puzzle has been solved.
Researchers from NHS Blood and Transplant, the International Blood Group Reference Laboratory in Bristol and the University of Bristol identified the genetic basis of the rare inherited AnWj negative phenotype. Their work showed that the antigen is carried by the Mal protein, which is encoded by the MAL gene. The discovery established a new blood group system called MAL.
The breakthrough may sound highly specialized. In reality, it touches one of the most fundamental questions in modern medicine: how precisely can doctors determine whether donated blood is safe for a particular person?
ABO and Rh remain the blood groups most people know. But human blood is far more complicated than those familiar letters suggest. Red blood cells carry hundreds of recognized antigens, and compatibility can become particularly challenging when a patient possesses a rare phenotype or develops an unusual antibody.
The discovery of the MAL system does not mean that millions of people suddenly have a new blood type they need to worry about. More than 99.9 percent of people are AnWj positive. The significance lies elsewhere: researchers now have a genetic explanation and a pathway toward better identification of the exceptionally rare people who are genetically AnWj negative.
That could matter enormously when one of those people needs blood.
Table of Contents
- The Breakthrough That Ended a 50 Year Mystery
- Blood Is More Complicated Than ABO and Rh
- What Was the AnWj Mystery?
- Why the Mystery Lasted Since 1972
- The Gene at the Centre of the Mystery
- How Scientists Used Genetic Sequencing
- How Researchers Proved MAL Was Responsible
- What Does AnWj Negative Actually Mean?
- Why This Matters for Blood Transfusions
- When Disease Can Temporarily Hide the Antigen
- Why Rare Blood Types Create a Special Medical Challenge
- The Search for Rare Donors
- The Future of Genetic Blood Typing
- What the Discovery Means Around the World
- Why Pakistan and South Asia Should Pay Attention
- From Blood Typing to Precision Medicine
- What the Discovery Does Not Mean
- What Comes Next
- Key Takeaways
- Conclusion
- Frequently Asked Questions
Facts at a Glance
- Mystery began: AnWj antigen identified in 1972.
- New blood group system: MAL.
- ISBT designation: MAL is blood group system 047.
- Antigen: AnWj.
- Responsible protein: Mal protein.
- Responsible gene: MAL.
- Frequency: More than 99.9 percent of people are AnWj positive.
- Rare phenotype: A very small number of people inherit AnWj negativity.
- Main scientific method: Whole exome sequencing combined with laboratory experiments.
- Potential clinical value: Better identification of rare patients and donors and improved transfusion matching.
The International Society of Blood Transfusion has subsequently ratified MAL as blood group system 047. Its database identifies MAL:1 as AnWj positive and MAL:-1 as AnWj negative, reflecting the genetic discoveries behind the system.
The Breakthrough That Ended a 50 Year Mystery
The story begins with a deceptively simple observation.
When scientists examine red blood cells, they can find molecules on the cell surface that act like biological identification markers. These structures are called antigens. The immune system can recognize them, and in some circumstances a person can produce antibodies against an antigen that their own red blood cells do not carry.
The AnWj antigen was discovered in 1972. Researchers could detect it serologically, meaning they could observe how antibodies reacted with blood cells. But identifying an antigen's presence is not the same thing as understanding its biological identity.
For decades, researchers knew that AnWj was extremely common but that a handful of people lacked it. The central question was simple to state and extraordinarily difficult to answer:
What genetic instruction tells a red blood cell to carry AnWj?
That question survived several generations of blood group research.
Researchers investigated other possible genes and proteins. Earlier work had connected the phenotype with molecules including CD44 and SMYD1, but those explanations did not ultimately account for the inherited AnWj negative phenotype across unrelated cases.
The decisive evidence eventually came from genetic sequencing and functional laboratory experiments.
INFOGRAPHIC 1 — THE 50 YEAR BLOOD GROUP MYSTERY
1972
AnWj antigen discovered
↓
Decades of investigation
Scientists identify the antigen but cannot establish its genetic basis
↓
Rare AnWj negative patients
Researchers investigate inherited cases
↓
Whole exome sequencing
DNA from rare cases is compared
↓
MAL gene identified
Large deletions are found in affected individuals
↓
Mal protein confirmed
Laboratory experiments establish that Mal carries AnWj
↓
MAL blood group system
The 50 year mystery is resolved
Blood Is More Complicated Than ABO and Rh
When people are asked about their blood type, the answer usually sounds familiar: A positive, B negative, AB positive or O negative.
Those labels are based on the ABO and Rh blood group systems. They are critically important, but they represent only part of the biological identity carried by red blood cells.
The International Society of Blood Transfusion recognizes many blood group systems. The formal ratification of MAL illustrates just how much complexity exists beneath the familiar ABO and Rh classifications. The ISBT report recorded 47 recognized blood group systems comprising 366 antigens as of June 2024, with MAL assigned system number 047.
That distinction matters because a patient can be perfectly matched for ABO and Rh and still possess other clinically important antibodies.
This is particularly relevant for people who require repeated transfusions. Patients with certain blood disorders, some cancers and other chronic conditions may receive blood products many times throughout their lives. Repeated exposure to foreign red cell antigens can increase the opportunity for antibody formation.
The challenge for transfusion medicine is therefore much bigger than simply asking whether someone is A, B, AB or O.
The deeper question is whether the donor's red cells carry antigens against which the recipient has clinically significant antibodies.
That is where discoveries such as MAL become important.
For readers interested in the broader relationship between modern medical technology and patient care, WorldAtNet has also examined technological advances in medicine in its recent analysis of robotic knee replacement.
What Was the AnWj Mystery?
AnWj is the name given to a particular antigen found on the surface of red blood cells.
The unusual name comes from the history of its discovery. According to the University of Bristol, AnWj was named after the first people associated with the antibody used to identify it, Anton and Wj.
The antigen is known as a high prevalence antigen because it is present in more than 99.9 percent of people.
That creates an unusual situation for transfusion medicine.
If almost everyone has an antigen, there are very few people who naturally lack it. Consequently, those rare individuals may be difficult to identify because routine blood typing does not necessarily search for every uncommon antigen.
Most importantly, an AnWj negative result can have more than one biological explanation.
Some people become AnWj negative because disease or other biological processes suppress expression of the antigen. A much smaller group has an inherited genetic form caused by changes in the MAL gene.
Distinguishing those situations is one of the reasons the genetic discovery matters.
Why the Mystery Lasted Since 1972
It is tempting to imagine that once scientists discover an unusual blood antigen, modern genetics should quickly reveal the responsible gene.
Human biology is rarely that straightforward.
A red blood cell contains a complicated collection of proteins, carbohydrates, membrane structures and other molecules. Some antigens are relatively easy to associate with a particular protein. Others are difficult because their expression can change according to disease, cell development or regulatory processes.
The AnWj problem was particularly difficult because the inherited phenotype was exceptionally rare.
Researchers cannot easily study a rare genetic condition when only a handful of individuals are known worldwide.
Each patient becomes scientifically important.
The Bristol research team examined individuals with the inherited AnWj negative phenotype and used whole exome sequencing to search for genetic changes shared by affected people.
The key finding was homozygosity for a large deletion in the MAL gene among the rare inherited cases. Further investigation found the same genetic explanation in additional unrelated AnWj negative individuals.
This was the genetic clue the field had been looking for.
The Gene at the Centre of the Mystery
The MAL gene provides instructions for producing a protein known as Mal, or myelin and lymphocyte protein.
Mal had not been an obvious candidate for explaining a blood group antigen.
That is one reason the discovery is scientifically interesting. Researchers were not simply confirming a protein that had always been suspected. They had to follow genetic evidence toward a protein whose role in red blood cells was not fully understood.
The research showed that AnWj positive red blood cells express full length Mal protein on their membranes.
In AnWj negative individuals, that protein was absent from the red cell membrane.
The study went further. Researchers introduced the normal MAL gene into an erythroid cell line, a laboratory model of developing red blood cells. The cells then expressed the AnWj antigen.
That experiment was particularly important because it moved the research beyond correlation.
The researchers were able to demonstrate that Mal was not merely associated with AnWj.
Mal was necessary and sufficient for AnWj expression.
How Scientists Used Genetic Sequencing
Whole exome sequencing is one of the tools that has transformed rare disease research.
The human genome contains enormous quantities of DNA, but only a relatively small fraction directly encodes proteins. The exome represents the protein coding portion of the genome.
Instead of searching through the entire genetic landscape without direction, researchers can examine protein coding regions for variants that might explain a particular biological characteristic.
For a common disease, researchers may be able to study thousands or millions of individuals.
For a rare blood phenotype, the numbers are radically different.
The Bristol research involved a tiny population of genetically AnWj negative individuals. The investigators compared their genetic information and looked for shared abnormalities that could plausibly explain the phenotype.
The discovery of the MAL deletion provided a strong candidate.
But genetic association alone is not enough to establish a blood group antigen.
Researchers needed to demonstrate that the gene actually produced the relevant antigen.
That required laboratory experimentation.
How Researchers Proved MAL Was Responsible
The strongest part of the discovery was the combination of genetic evidence with functional evidence.
First, researchers found the MAL deletion in inherited AnWj negative individuals.
Second, they showed that AnWj positive red cells carried the Mal protein while AnWj negative cells did not.
Third, they examined antibody binding.
Anti AnWj antibodies reacted with the relevant protein structure. Experiments demonstrated that antibodies directed against AnWj and antibodies directed against Mal recognized the same molecular target.
Finally, researchers introduced the normal MAL gene into an erythroid cell model.
The AnWj antigen appeared.
This sequence of evidence is what transformed an intriguing genetic association into a convincing biological explanation.
Science often advances not because one experiment produces a spectacular result, but because several independent lines of evidence point toward the same answer.
INFOGRAPHIC 2 — FROM DNA TO BLOOD GROUP
DNA
The MAL gene contains genetic instructions.
↓
MAL gene
Provides instructions for Mal protein.
↓
Mal protein
Becomes part of the red blood cell membrane.
↓
AnWj antigen
The antigen recognized by anti AnWj antibodies is expressed.
↓
Blood phenotype
The person is AnWj positive.
When both copies of MAL carry the relevant deletion
Mal protein is absent and the inherited AnWj negative phenotype can occur.
What Does AnWj Negative Actually Mean?
AnWj negative does not mean that someone is sick.
This distinction is extremely important.
The University of Bristol reported that people with the inherited AnWj negative phenotype identified in the research were healthy. The inherited form is exceptionally rare.
There is another pathway to AnWj negativity, however.
Certain diseases can suppress expression of the antigen. The University of Bristol notes that haematological disorders and some cancers can reduce or suppress Mal expression, creating an acquired AnWj negative phenotype.
This means that an AnWj negative test does not automatically tell doctors that the patient has an inherited MAL mutation.
The underlying cause has to be investigated in context.
That distinction also helps explain why the discovery of MAL is clinically useful. Genetic testing may eventually help laboratories distinguish inherited cases from acquired suppression.
Why This Matters for Blood Transfusions
Blood transfusion is one of modern medicine's most important life saving interventions.
People may need transfusions after major trauma, during complex surgery, because of severe anaemia, during cancer treatment or because of chronic blood disorders.
The World Health Organization estimates that nearly 120 million units of blood are donated worldwide each year, while emphasizing that global supplies remain insufficient for the needs of many patients.
Safe transfusion therefore depends on two interconnected systems.
The first is having enough blood.
The second is making sure the blood is appropriate for the person receiving it.
ABO incompatibility can cause severe and potentially fatal haemolytic reactions. But ABO is not the only consideration in transfusion medicine.
Other antibodies can also create compatibility problems.
The AnWj story illustrates the challenge at the extreme end of this spectrum.
If a genetically AnWj negative person develops clinically significant anti AnWj antibodies and receives AnWj positive blood, there can be a risk of a transfusion reaction. The University of Bristol specifically notes that identifying such patients can help reduce transfusion associated complications.
The challenge is that an extremely rare patient may not be easy to identify until a complex transfusion problem occurs.
When Disease Can Temporarily Hide the Antigen
One of the most fascinating aspects of the AnWj system is that genetics is not the only story.
A person's red blood cells can stop expressing certain antigens because of disease related biological changes.
In the case of AnWj, haematological disorders and some cancers can suppress expression of the antigen.
This creates a biological puzzle.
A person may appear AnWj negative because they have inherited a mutation affecting MAL. Another patient may become AnWj negative because an illness has suppressed expression of the same protein.
The blood test may show a similar phenotype while the underlying biology is completely different.
This is one reason modern transfusion medicine increasingly combines conventional serology with molecular testing.
The more precisely laboratories can understand the genetic background of a patient's blood cells, the more accurately they can interpret unusual blood group findings.
It is another example of a broader transformation in medicine: doctors are increasingly moving from observing biological characteristics to identifying the molecular instructions behind them.
WorldAtNet has explored another side of this movement in its recent report on human brain organoids and next generation disease research, where researchers are also using human derived biological models to investigate mechanisms that conventional approaches cannot fully reproduce.
Why Rare Blood Types Create a Special Medical Challenge
Rare blood groups create an unusual logistical problem.
Suppose a hospital has a patient who urgently needs red blood cells.
The patient's ABO and Rh type may be known, but further testing reveals an uncommon antibody. The laboratory now needs to find donor blood lacking the antigen targeted by that antibody.
If that antigen is extremely common in the general population, compatible donors may be extraordinarily difficult to find.
This is where rare donor programmes become important.
Blood services maintain databases of donors with unusual antigen profiles. When a patient with a rare blood requirement is identified, these databases can help laboratories search for compatible units.
The discovery of the MAL genetic basis provides another tool for that process.
Instead of relying entirely on antibody based testing, laboratories can potentially use genetic information to identify people who carry rare blood group phenotypes.
That could make rare donor identification more systematic.
The Search for Rare Donors
Finding a rare donor is not the same as finding a rare blood type on a laboratory report.
A donor must be correctly identified, tested, registered and available when a patient requires compatible blood.
That is why rare donor networks are an important part of modern transfusion infrastructure.
The University of Bristol said the MAL discovery should make it easier to identify genetically AnWj negative donors and patients and that genotyping tests can potentially be incorporated into existing platforms.
The practical value could become particularly important when a patient is undergoing planned surgery or requires repeated transfusion.
If doctors know beforehand that someone has an exceptionally rare blood phenotype, the transfusion service has more time to investigate compatible units.
In an emergency, that preparation can become extremely valuable.
The Future of Genetic Blood Typing
Traditional blood typing relies heavily on serology.
In simple terms, laboratory scientists test how red blood cells react with known antibodies. The pattern of reactions reveals which antigens are present or absent.
Genotyping approaches the problem from another direction.
Instead of asking only what is visible on the cell surface, genetic testing asks which variants are present in the patient's DNA.
Neither approach automatically replaces the other.
Serology remains fundamental because what matters clinically is how the patient's red cells and antibodies behave.
But genetic information can provide additional detail, especially when a phenotype is difficult to interpret.
The MAL discovery is therefore part of a larger trend toward molecular blood group typing.
As genetic sequencing becomes faster and more accessible, transfusion laboratories may increasingly build detailed molecular profiles of patients who require repeated transfusions.
Those profiles could help clinicians select blood more precisely.
That is particularly relevant for patients who receive chronic transfusion therapy and therefore face repeated exposure to donor antigens.
INFOGRAPHIC 3 — THE FUTURE OF PRECISION BLOOD MATCHING
STEP 1 — Patient sample
Blood and, where appropriate, DNA are analysed.
↓
STEP 2 — Molecular profile
Relevant blood group genes and variants are identified.
↓
STEP 3 — Antibody profile
Clinicians determine whether clinically significant antibodies are present.
↓
STEP 4 — Donor database
Rare compatible donors can be searched using detailed antigen information.
↓
STEP 5 — Compatible blood
The transfusion service selects blood appropriate for the patient's requirements.
↓
STEP 6 — Safer transfusion
Better matching can reduce the risk of certain transfusion complications.
What the Discovery Means Around the World
The MAL discovery was made through an international scientific effort involving researchers and blood services in the United Kingdom and collaborators elsewhere.
That international dimension is important because rare blood phenotypes do not respect national borders.
A patient may live in one country while the only compatible donor identified for a particular blood phenotype is located thousands of kilometres away.
Modern transfusion medicine therefore depends increasingly on international knowledge sharing, standardized blood group terminology and sophisticated donor registries.
The International Society of Blood Transfusion plays an important role in maintaining internationally recognized blood group classifications.
Its formal recognition of MAL as blood group system 047 means that the discovery is no longer simply a research finding. It has become part of the standardized scientific framework used to describe human blood group systems.
That standardization matters because laboratories in different countries need to be able to describe the same blood phenotype in the same language.
In rare transfusion medicine, terminology is not merely academic.
It can become part of patient safety.
Why Pakistan and South Asia Should Pay Attention
The MAL discovery may have emerged from laboratories in Bristol, but the underlying lesson is global.
Countries with large populations and substantial transfusion needs also need increasingly sophisticated systems for identifying unusual blood groups.
Pakistan has a major need for reliable blood collection, testing, storage and distribution because transfusion is used across surgery, trauma, obstetric care, cancer treatment and inherited blood disorders.
The challenge becomes particularly significant for patients who need repeated transfusions.
For example, people living with transfusion dependent blood disorders can accumulate exposure to many donor red cell antigens over time. Better antigen matching can therefore become an important part of long term transfusion management.
The MAL discovery does not mean that Pakistani hospitals should suddenly test every person for the MAL system. The phenotype is extremely rare, and routine clinical testing decisions depend on local laboratory capabilities and patient circumstances.
The broader lesson is more important.
Investment in modern blood services increasingly means investment not only in blood collection but also in laboratory genetics, quality systems, donor registries, reference laboratories and reliable information exchange.
The WHO's 2026 global report on blood safety and availability emphasizes the continuing need to strengthen national blood systems, laboratory screening, governance, quality assurance and equitable access to safe blood.
For countries across South Asia, the development of advanced blood typing should therefore be seen as part of a broader healthcare modernization process.
From Blood Typing to Precision Medicine
The MAL discovery represents something larger than the solution to one unusual blood group puzzle.
It demonstrates how precision medicine increasingly works.
Traditional medicine often begins with visible characteristics.
A patient has a symptom. A laboratory test shows an abnormality. A clinician identifies a disease.
Modern molecular medicine tries to go deeper.
Why does this patient have this phenotype?
Which gene is involved?
Which protein is affected?
How does that protein alter cell behaviour?
Can the genetic information improve diagnosis or treatment?
The MAL story follows that entire chain.
Researchers started with an unusual red cell phenotype. They investigated its inheritance. They sequenced DNA. They identified a candidate gene. They examined the associated protein. They performed functional experiments. They established the relationship between the gene, protein and antigen.
The result is a much more complete biological explanation.
That is precision medicine in miniature.
What the Discovery Does Not Mean
Scientific breakthroughs are often simplified by headlines.
That can create misunderstandings.
The discovery of MAL does not mean that doctors have found a new common blood type comparable to A, B, AB or O.
It does not mean that most people need a new blood test.
It does not mean that conventional ABO and Rh testing is becoming obsolete.
It does not mean that every AnWj negative person has a dangerous inherited mutation.
And it does not mean that transfusion reactions caused by every blood group antigen can now be prevented.
The actual significance is more precise.
Scientists have identified the genetic and molecular basis of a rare inherited AnWj negative phenotype. That knowledge can support the development of genetic tests and improve the ability of blood services to identify rare patients and donors.
That may sound less dramatic than saying medicine has discovered a mysterious new blood type.
Scientifically, however, it is far more meaningful.
What Comes Next
The discovery is not the end of the story.
It is the beginning of a new phase.
The first priority will be developing and validating practical genotyping approaches capable of identifying relevant MAL variants.
Blood services will also need to determine how those tests should be incorporated into existing workflows.
Researchers may continue studying the biological function of Mal in red blood cells. Understanding what the protein does in the cell membrane could reveal additional information about why it carries the AnWj antigen and how its absence affects red cell biology.
Another important area is population genetics.
Because the inherited phenotype is so rare, researchers still need more information about its distribution across populations.
The University of Bristol has emphasized that the number of genetically AnWj negative individuals known to science is extremely small and that it is not yet established whether the phenotype is more common in any particular ethnic population.
That is an important scientific caution.
The presence of several reported cases from a particular region does not automatically mean that the blood phenotype is common among everyone from that population.
More genetic data are required.
Future discoveries may also reveal additional rare blood group systems whose molecular identities remain unresolved.
The history of AnWj demonstrates why that work matters.
A blood antigen can remain biologically mysterious for decades until advances in sequencing, laboratory technology and international collaboration finally make the answer visible.
Why This 50 Year Mystery Matters to Ordinary People
For most people, blood typing is something they encounter only when donating blood, preparing for surgery, becoming pregnant, being treated for severe anaemia or facing an emergency.
That can make transfusion medicine seem like a background laboratory service.
In reality, it is one of the invisible foundations of modern healthcare.
When a trauma patient arrives in an emergency department, blood may need to be available quickly.
When a patient undergoes major surgery, blood products may be needed within minutes.
When someone with a chronic blood disorder requires another transfusion, the medical team needs to consider not only the immediate need but also the patient's history of antibodies and previous transfusions.
Behind all of those situations is an enormous scientific infrastructure.
Blood groups have to be classified. Donors have to be tested. Units have to be screened. Compatibility has to be assessed. Rare phenotypes have to be recognized. Records have to be maintained.
The MAL discovery improves one small but important part of that knowledge.
And sometimes small pieces of scientific knowledge have surprisingly large consequences when they are inserted into a complex healthcare system.
From a Forgotten Antigen to a Recognized Blood Group
There is something remarkable about the timeline.
In 1972, scientists could see the biological clue.
For decades, they could not explain it.
Then modern genetics changed the investigation.
Researchers found rare inherited cases. DNA sequencing pointed toward MAL. Laboratory experiments demonstrated the role of the Mal protein. Antibody binding experiments strengthened the conclusion. The evidence ultimately supported the creation of a new blood group system.
The International Society of Blood Transfusion subsequently recognized MAL as system 047.
The story is a useful reminder that scientific progress is rarely linear.
A mystery may survive not because researchers are ignoring it, but because the necessary technology does not yet exist.
When that technology arrives, an apparently impossible question can sometimes become solvable.
Key Takeaways
- AnWj is not a newly discovered antigen. It was identified in 1972, but its genetic basis remained unresolved for decades.
- MAL is now an officially recognized blood group system. The ISBT lists MAL as system 047.
- The MAL gene encodes Mal protein. Researchers demonstrated that the protein carries the AnWj antigen on red blood cells.
- Most people are AnWj positive. More than 99.9 percent of people express the antigen.
- Inherited AnWj negativity is extremely rare. Only a small number of genetically AnWj negative individuals have been identified.
- Disease can also suppress AnWj expression. This means inherited and acquired forms need to be distinguished.
- The discovery matters most for rare transfusion situations. An AnWj negative patient with clinically significant anti AnWj antibodies may require compatible blood.
- Genetic testing could improve rare donor identification. The discovery provides the foundation for MAL genotyping.
- The breakthrough illustrates the growth of precision medicine. Researchers moved from a visible blood phenotype to its genetic and molecular explanation.
- The discovery does not replace ordinary blood typing. ABO and Rh testing remain fundamental to safe transfusion.
Conclusion: The Hidden Complexity Inside Every Drop of Blood
For more than 50 years, the AnWj antigen was a biological question without a satisfactory genetic answer.
Scientists knew it existed. They knew it was widespread. They knew a tiny number of people lacked it. They knew antibodies against it could become relevant to transfusion medicine.
But the molecular explanation remained hidden.
The discovery of the MAL gene and Mal protein finally connected the pieces.
What began with a blood sample in 1972 eventually became a modern genetic investigation involving rare patients, whole exome sequencing, molecular biology and carefully designed laboratory experiments.
The result is not simply another entry in a medical database.
It gives transfusion scientists a better way to understand an exceptionally rare blood phenotype and potentially a better way to identify patients and donors who may otherwise be difficult to recognize.
The story also illustrates something fundamental about modern medicine.
The human body still contains mysteries that can survive for decades even in an age of genome sequencing and advanced imaging. But when genetics, laboratory science, clinical medicine and international collaboration come together, some of those mysteries can finally be solved.
There are hundreds of recognized blood group antigens, and the discovery of MAL suggests that the map of human blood biology is still being refined.
For most people, the practical message is simple: nothing about an ordinary A positive, B negative or O positive blood type has suddenly changed.
For the tiny number of people whose blood carries an exceptionally rare phenotype, however, better genetic knowledge could eventually make a critical difference.
And that may be the most important lesson from this 50 year mystery.
Sometimes the smallest molecular discovery can make the biggest difference when medicine has to find exactly the right blood for exactly the right patient.
Frequently Asked Questions
What is the MAL blood group?
MAL is a formally recognized human blood group system containing the AnWj antigen. The International Society of Blood Transfusion lists MAL as blood group system 047.
What is AnWj?
AnWj is a high prevalence red blood cell antigen first identified in 1972. It is present in more than 99.9 percent of people.
What gene causes inherited AnWj negativity?
Researchers identified deletions in the MAL gene as the genetic basis of the rare inherited AnWj negative phenotype.
Does AnWj negative mean someone is sick?
No. People with the inherited AnWj negative phenotype can be healthy. AnWj expression can also be suppressed by certain diseases, creating an acquired form of AnWj negativity.
Can an AnWj negative person receive normal blood?
Transfusion decisions depend on the patient's complete blood group and antibody profile. If clinically significant anti AnWj antibodies are present, compatible blood may be required. Blood transfusion should always be managed by qualified transfusion specialists.
Is MAL the same thing as ABO?
No. MAL and ABO are separate blood group systems. ABO determines the familiar A, B, AB and O categories, while MAL concerns the AnWj antigen.
Is MAL the same thing as Rh?
No. Rh is another independent blood group system. A person's ABO, Rh and other clinically relevant blood group characteristics can all be considered during transfusion testing.
Why did scientists need 50 years to solve the mystery?
The inherited phenotype is extremely rare, making genetic investigation difficult. The relevant gene was also not an obvious candidate, and researchers needed several independent experiments to establish that Mal actually carries the AnWj antigen.
Can genetic testing identify MAL blood group status?
The discovery provides the genetic foundation for MAL genotyping. Researchers have indicated that such tests can potentially be incorporated into existing blood group genotyping platforms.
Will ordinary people need a MAL blood test?
Not necessarily. MAL is an extremely rare blood group issue, and routine blood testing decisions depend on clinical circumstances. People should not seek specialized testing simply because they have read about the discovery.
Why are rare blood groups important?
Rare blood groups become especially important when a patient has an antibody against a high prevalence antigen. In such circumstances, finding compatible donor blood can be difficult.
What is the biggest significance of the discovery?
The major significance is that scientists now understand the genetic and molecular basis of the inherited AnWj negative phenotype. That knowledge can improve identification of rare patients and donors and support safer transfusion strategies.
Sources and Further Reading
University of Bristol: Researchers discover new blood group system MAL and explain the 50 year AnWj mystery.
Blood / American Society of Hematology: Original research identifying MAL deletions and establishing the molecular basis of the inherited AnWj negative phenotype.
International Society of Blood Transfusion: International classification and recognition of the MAL blood group system.
ISBT Blood Group Database: MAL system information, including AnWj positive and negative phenotypes.
World Health Organization: Global information on blood transfusion safety and availability.
Medical disclaimer: This article is intended for general education and health awareness. It does not diagnose blood group disorders or determine whether a particular blood product is suitable for an individual. Blood compatibility and transfusion decisions must be made by qualified clinicians and transfusion medicine laboratories.
Recommended WorldAtNet Internal Reading
Inside the Gut at 20 Nanometers: The New Microscope Searching for the Root Cause of Crohn’s Disease
The Human Brain in a Lab: How Scientists Are Building New Models to Understand Neurological Disease
Robotic Knee Replacement: How Technology Improves Surgical Precision
The Artificial Kidney Revolution: Could Wearable and Implantable Devices Finally Change Dialysis?
Chronic Inflammation: The Hidden Health Threat Behind Modern Disease
0 Comments